Timolol maleate 0.5%/sorbitol complex is a convenient, well-tolerated choice for adjunctive therapy in patients taking a prostaglandin analogue who need further IOP control.
Switching to another prostaglandin analogue that does not contain benzalkonium chloride may not be the answer for managing complaints from patients of dryness and irritation.
Novartis plans to assume complete control over Alcon Laboratories in a two-step process that some analysts and some members of Alcon's board of directors are challenging for its fairness under U.S. and Swiss merger laws.
After decades of giving pharmaceutical treatment options for glaucoma, Alcon Laboratories plans to add a surgical treatment option by acquiring Optonol Ltd.
This has been a year filled with many exciting developments in cataract surgery.
As attendees gather for the Wilmer Eye Institute's 22nd annual Current Concepts in Ophthalmology meeting, they can expect the agenda to focus on clinical use and medical issues important to ophthalmology.
Interim results from the first human pharmacokinetic study of an investigational extended-release intravitreal device for the treatment of diabetic macular edema suggest that it has both significant efficacy and a favorable side effect profile.
New data from phase III clinical trials of dexamethasone 0.7 mg intravitreal implant reaffirm that this novel pharmacotherapeutic intervention is well-tolerated and effectively improves vision in patients with macular edema secondary to a branch or central retinal vein occlusion.
Boca Raton, FL—New FDA-approved technology (Vision Restoration Therapy, Nova Vision Inc.) delivers a custom-designed pattern of light of varying intensity to the edges of the visual field to increase the field in patients whose vision is impaired due to stroke, according to recently reported research.